Dasatinib is a tyrosine kinase inhibitor that is commonly used in the treatment of certain cancers, particularly chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). It is a potent inhibitor of the BCR-ABL kinase as well as other kinases such as SRC, c-KIT, and PDGFR. Dasatinib works by blocking the activity of these enzymes, thereby inhibiting the proliferation of cancer cells.
